insulin aspart

Active substance
insulin aspart
Domain
Metabolism and Endocrinology
Reason of inclusion in Horizonscan Geneesmiddelen
Biosimilar
Main indication
Diabetes
Extended indication
The treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

1. Product

Current proprietary name
NovoRapid (Novo Nordisk)
Mechanism of action
Receptor agonist

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
November 2019
Expected Registration
November 2020
Registration phase
Registration application pending
Additional comments
SPC is inmiddels verlopen

3. Therapeutic value

Therapeutic value
Potential equal value
Duration of treatment
Not found

4. Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

5. Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

6. Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.